Objective: This review explores the relationship between ADHD and substance use disorder (SUD), factors that determine the abuse potential of psychostimulants, and strategies for identifying and treating at-risk ADHD patients. Method: This study uses a Medline review of literature. Results: Psychostimulants, such as methylphenidate and amphetamines, are effective first-line pharmacotherapy for ADHD and when used appropriately in individuals with ADHD do not appear to be frequently abused by patients. Diversion and misuse of prescription stimulants are growing concerns, especially among young adults and college students. Short-acting psychostimulant formulations may have higher potential for abuse, misuse, and diversion, but more data are needed to substantiate this observation. Nonstimulant treatments for ADHD may be considered for patients at particularly high risk for substance use, misuse, or diversion of stimulants. Conclusion: In treating patients with ADHD and comorbid substance use, psychostimulants may be a useful pharmacologic alternative. However, the risks of such treatment with high-risk populations must be considered alongside potential benefits. (J. of Att. Dis. 2008; 12(2) 115-125)
Adler, L.A., Resnick, S., Kunz, M., & Devinsky, O. (1995). Open-label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacology Bulletin, 31(4), 785-788.
2.
Advokat, C. (2007). Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD. Journal of Attention Disorders, 11(1), 8-16.
3.
Andersen, S.L., Arvanitogiannis, A., Pliakas, A.M., LeBlanc, C., & Carlezon, W.A. , Jr. (2002). Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nature Neuroscience, 5(1), 13-14.
4.
August, G.J., Winters, K.C., Realmuto, G.M., Fahnhorst, T., Botzet, A., & Lee, S. (2006). Prospective study of adolescent drug use among community samples of ADHD and non-ADHD participants. Journal of the American Academy of Child and Adolescent Psychiatry, 45(7), 824-832.
5.
Babcock, Q., & Byrne, T. (2000). Student perceptions of methylphenidate abuse at a public liberal arts college. Journal of American College Health, 49(3), 143-145.
6.
Balster, R.L., & Schuster, C.R. (1973). Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. Journal of the Experimental Analysis of Behavior, 20(1), 119-129.
7.
Barkley, R.A. (2004). Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatric Clinics of North America, 27(2), 233-260.
8.
Barkley, R.A., Fischer, M., Edelbrock, C.S., & Smallish, L. (1990). The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. Journal of the American Academy of Child and Adolescent Psychiatry, 29(4), 546-557.
9.
Barrett, S.P., Darredeau, C., & Pihl, R.O. (2006). Patterns of simultaneous polysubstance use in drug using university students. Human Psychopharmacology, 21(4), 255-263.
10.
Biederman, J., Boellner, S.W., Childress, A., Lopez, F.A., & Krishnan, S. (2006, October). Improvements in symptoms of attention-deficit/hyperactivity disorder in school-aged children with lisdexamfetamine (NRP104) and mixed amphetamine salts, extended-release versus placebo. Paper presented at the 58th Institute on Psychiatric Services, New York.
11.
Biederman, J., Faraone, S.V., Spencer, T.J., Mick, E., Monuteaux, M.C., & Aleardi, M. (2006). Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community. Journal of Clinical Psychiatry, 67(4), 524-540.
12.
Biederman, J., Monuteaux, M.C., Mick, E., Spencer, T., Wilens, T.E., Silva, J.M., et al. (2006). Young adult outcome of attention deficit hyperactivity disorder: A controlled 10-year follow-up study. Psychological Medicine, 36(2), 167-179.
13.
Biederman, J., Wilens, T., Mick, E., Faraone, S.V., Weber, W., Curtis, S., et al. (1997). Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study . Journal of the American Academy of Child and Adolescent Psychiatry, 36(1), 21-29.
14.
Biederman, J., Wilens, T., Mick, E., Milberger, S., Spencer, T.J., & Faraone, S.V. (1995). Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): Effects of ADHD and psychiatric comorbidity. American Journal of Psychiatry, 152(11), 1652-1658.
15.
Biederman, J., Wilens, T., Mick, E., Spencer, T., & Faraone, S.V. (1999). Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics , 104(2), e20.
16.
Brandon, C.L., Marinelli, M., & White, F.J. (2003). Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons. Biological Psychiatry, 54(12), 1338-1344.
17.
Carpentier, P.J., de Jong, C.A., Dijkstra, B.A., Verbrugge, C.A., & Krabbe, P.F. (2005). A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders . Addiction, 100(12), 1868-1874.
18.
Carroll, K.M., & Rounsaville, B.J. (1993). History and significance of childhood attention deficit disorder in treatment-seeking cocaine abusers . Comprehensive Psychiatry, 34(2), 75-82.
19.
Castaneda, R., Levy, R., Hardy, M., & Trujillo, M. (2000). Long-acting stimulants for the treatment of attention-deficit disorder in cocaine-dependent adults. Psychiatric Services , 51(2), 169-171.
20.
Coetzee, M., Kaminer, Y., & Morales, A. (2002). Megadose intranasal methylphenidate (ritalin) abuse in adult attention deficit hyperactivity disorder. Substance Abuse, 23(3), 165-169.
21.
DeVore, E.R., & Ginsburg, K.R. (2005). The protective effects of good parenting on adolescents. Current Opinion in Pediatrics , 17(4), 460-465.
22.
Di Chiara, G., & Imperato, A. (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Sciences of the United States of America, 85(14), 5274-5278.
23.
Faraone, S.V., & Biederman, J. (2004, May). Prevalence of adult ADHD in the United States . Paper presented at the 157th American Psychiatric Association annual meeting, New York.
24.
Faraone, S.V., Biederman, J., Wilens, T.E., & Adamson, J. (2007). A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults. Psychological Medicine, 37, 1-10.
25.
Flory, K., Milich, R., Lynam, D.R., Leukefeld, C., & Clayton, R. (2003). Relation between childhood disruptive behavior disorders and substance use and dependence symptoms in young adulthood: Individuals with symptoms of attention-deficit/hyperactivity disorder and conduct disorder are uniquely at risk. Psychology of Addictive Behaviors, 17(2), 151-158.
26.
Fredericks, E.M., & Kollins, S.H. (2004). Assessing methylphenidate preference in ADHD patients using a choice procedure. Psychopharmacology, 175(4), 391-398.
27.
Gordon, S.M., Tulak, F., & Troncale, J. (2004). Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence. Journal of Addictive Diseases, 23(4), 31-40.
28.
Greenhill, L.L., Pliszka, S., Dulcan, M.K., Bernet, W., Arnold, V., Beitchman, J., et al. (2002). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry, 41(Suppl. 2), 26S-49S.
29.
Heil, S.H., Holmes, H.W., Bickel, W.K., Higgins, S.T., Badger, G.J., Laws, H.F., et al. (2002). Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users . Drug and Alcohol Dependence, 67(2), 149-156.
30.
Huss, M., & Lehmkuhl, U. (2002). Methylphenidate and substance abuse: A review of pharmacology, animal, and clinical studies. Journal of Attention Disorders, 6(Suppl. 1), S65-S71.
31.
Johnston, L.D., O'Malley, P.M., Bachman, J.G., & Schulenberg, J.E. (2004). Overall teen drug use continues gradual decline; but use of inhalants rises. Retrieved March 12, 2007, from http://www.monitoringthefuture.org/pressreleases/04drugpr.pdf
32.
Katusic, S.K., Barbaresi, W.J., Colligan, R.C., Weaver, A.L., Leibson, C.L., & Jacobsen, S.J. (2005). Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: A population-based, birth cohort study. Journal of Child and Adolescent Psychopharmacology, 15(5), 764-776.
33.
Kelley, A.E., Schochet, T., & Landry, C.F. (2004). Risk taking and novelty seeking in adolescence: Introduction to partI. Annals of the New York Academy of Sciences, 1021, 27-32.
34.
Kessler, R.C., Adler, L., Barkley, R., Biederman, J., Conners, C.K., Demler, O., et al. (2006). The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication . American Journal of Psychiatry, 163(4), 716-723.
35.
Klein-Schwartz, W., & McGrath, J. (2003). Poison centers' experience with methylphenidate abuse in pre-teens and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 42(3), 288-294.
36.
Kollins, S.H. (2003). Comparing the abuse potential of methylphenidate versus other stimulants: A review of available evidence and relevance to the ADHD patient. Journal of Clinical Psychiatry, 64(Suppl. 11), 14-18.
37.
Kollins, S.H., MacDonald, E.K., & Rush, C.R. (2001). Assessing the abuse potential of methylphenidate in nonhuman and human subjects: A review. Pharmacology, Biochemistry, and Behavior, 68(3), 611-627.
38.
Kollins, S.H., Rush, C.R., Pazzaglia, P.J., & Ali, J.A. (1998). Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Experimental and Clinical Psychopharmacology, 6(4), 367-374.
39.
Koob, G.F. (2000). Stimulants: Basic mechanisms and pharmacology . In M. H. Kryger, R. Roth, & W. C. Dement (Eds.), Principles and practice of sleep medicine (pp. 419-428). Philadelphia: W. B. Saunders.
40.
Koob, G.F., & Nestler, E.J. (1997). The neurobiology of drug addiction. Journal of Neuropsychiatry and Clinical Neurosciences, 9(3), 482-497.
41.
Lambert, N.M., & Hartsough, C.S. (1998). Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants . Journal of Learning Disabilities, 31(6), 533-544.
42.
Levin, F.R., Evans, S.M., McDowell, D.M., & Kleber, H.D. (1998). Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: A pilot study. Journal of Clinical Psychiatry, 59(6), 300-305.
43.
Lile, J.A., Stoops, W.W., Durell, T.M., Glaser, P.E., & Rush, C.R. (2006). Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans . Experimental and Clinical Psychopharmacology, 14(2), 136-147.
44.
MacDonald, F.E., & Kollins, S.H. (2005). A pilot study of methylphenidate preference assessment in children diagnosed with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 15(5), 729-741.
45.
Mague, S.D., Andersen, S.L., & Carlezon, W.A. , Jr. (2005). Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats. Biological Psychiatry, 57(2), 120-125.
46.
Mannuzza, S., Klein, R.G., Bonagura, N., Malloy, P., Giampino, T.L., & Addalli, K.A. (1991). Hyperactive boys almost grown up. V. Replication of psychiatric status. Archives of General Psychiatry, 48(1), 77-83.
47.
Mannuzza, S., Klein, R.G., & Moulton, J.L., III. (2003). Does stimulant treatment place children at risk for adult substance abuse? A controlled, prospective follow-up study. Journal of Child and Adolescent Psychopharmacology , 13(3), 273-282.
48.
McCabe, S.E., Cranford, J.A., Morales, M., & Young, A. (2006). Simultaneous and concurrent polydrug use of alcohol and prescription drugs: Prevalence, correlates, and consequences. Journal of Studies on Alcohol, 67(4), 529-537.
49.
McCabe, S.E., Knight, J.R., Teter, C.J., & Wechsler, H. (2005). Non-medical use of prescription stimulants among US college students: Prevalence and correlates from a national survey. Addiction, 100(1), 96-106.
50.
McCabe, S.E., Teter, C.J., & Boyd, C.J. (2006a). Medical use, illicit use, and diversion of abusable prescription drugs. Journal of American College Health, 54(5), 269-278.
51.
McCabe, S.E., Teter, C.J., & Boyd, C.J. (2006b). Medical use, illicit use and diversion of prescription stimulant medication. Journal of Psychoactive Drugs, 38(1), 43-56.
52.
McGough, J.J., Smalley, S.L., McCracken, J.T., Yang, M., Del'Homme, M., Lynn, D.E., et al. (2005). Psychiatric comorbidity in adult attention deficit hyperactivity disorder: Findings from multiplex families. American Journal of Psychiatry, 162(9), 1621-1627.
53.
Michelson, D., Allen, A.J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., et al. (2002). Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. American Journal of Psychiatry, 159(11), 1896-1901.
54.
Milberger, S., Biederman, J., Faraone, S.V., Wilens, T., & Chu, M.P. (1997). Associations between ADHD and psychoactive substance use disorders. Findings from a longitudinal study of high-risk siblings of ADHD children. American Journal on Addiction, 6(4), 318-329.
55.
Piazza, P.V., Deminiere, J.M., le Moal, M., & Simon, H. (1989). Factors that predict individual vulnerability to amphetamine self-administration. Science, 245(4925), 1511-1513.
56.
Piazza, P.V., Deminiere, J.M., le Moal, M., & Simon, H. (1990). Stress- and pharmacologically-induced behavioral sensitization increases vulnerability to acquisition of amphetamine self-administration . Brain Research, 514(1), 22-26.
57.
Rapoport, J.L., Buchsbaum, M.S., Weingartner, H., Zahn, T.P., Ludlow, C., & Mikkelsen, E.J. (1980). Dextroamphetamine. Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Archives of General Psychiatry, 37(8), 933-943.
58.
Resnick, R.B., Kestenbaum, R.S., & Schwartz, L.K. (1977). Acute systemic effects of cocaine in man: A controlled study by intranasal and intravenous routes . Science, 195(4279), 696-698.
59.
Robinson, T.E., & Becker, J.B. (1986). Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis. Brain Research, 396(2), 157-198.
60.
Rush, C.R., Kollins, S.H., & Pazzaglia, P.J. (1998). Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. Experimental and Clinical Psychopharmacology, 6(1), 32-44.
61.
Schenk, S., & Partridge, B. (1997). Sensitization and tolerance in psychostimulant self-administration. Pharmacology, Biochemistry, and Behavior , 57(3), 543-550.
62.
Schiffer, W.K., Volkow, N.D., Fowler, J.S., Alexoff, D.L., Logan, J., & Dewey, S.L. (2006). Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse, 59(4), 243-251.
63.
Schubiner, H., Saules, K.K., Arfken, C.L., Johanson, C.E., Schuster, C.R., Lockhart, N., et al. (2002). Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Experimental and Clinical Psychopharmacology, 10(3), 286-294.
64.
Schubiner, H., Tzelepis, A., Milberger, S., Lockhart, N., Kruger, M., Kelley, B.J., et al. (2000). Prevalence of attention-deficit/ hyperactivity disorder and conduct disorder among substance abusers. Journal of Clinical Psychiatry, 61(4), 244-251.
65.
Spear, L.P. (2004). Adolescent brain development and animal models . Annals of the New York Academy of Sciences, 1021, 23-26.
66.
Spencer, T.J., Biederman, J., Ciccone, P.E., Madras, B.K., Dougherty, D.D., Bonab, A.A., et al. (2006). PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. American Journal of Psychiatry , 163(3), 387-395.
67.
Substance Abuse and Mental Health Services Administration, Office of Applied Studies. (2006). Results from the 2005 National Survey on Drug Use and Health: National findings. Rockville, MD: Author.
68.
Swanson, J., Gupta, S., Lam, A., Shoulson, I., Lerner, M., Modi, N., et al. (2003). Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Proof-of-concept and proof-of-product studies. Archives of General Psychiatry, 60(2), 204-211.
69.
Teter, C.J., McCabe, S.E., LaGrange, K., Cranford, J.A., & Boyd, C.J. (2006). Illicit use of specific prescription stimulants among college students: Prevalence, motives, and routes of administration . Pharmacotherapy, 26(10), 1501-1510.
70.
Volkow, N.D. (2006). Stimulant medications: How to minimize their reinforcing effects? American Journal of Psychiatry, 163(3), 359-361.
71.
Volkow, N.D., Ding, Y.S., Fowler, J.S., Wang, G.J., Logan, J., Gatley, J.S., et al. (1995). Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Archives of General Psychiatry, 52(6), 456-463.
72.
Volkow, N.D., Fowler, J.S., Wang, G.J., Ding, Y.S., & Gatley, S.J. (2002). Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: Results from imaging studies. European Neuropsychopharmacology, 12(6), 557-566.
73.
Volkow, N.D., & Swanson, J.M. (2003). Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. American Journal of Psychiatry, 160(11), 1909-1918.
74.
Wilens, T.E. (2004). Attention-deficit/hyperactivity disorder and the substance use disorders: The nature of the relationship, subtypes at risk, and treatment issues. Psychiatric Clinics of North America , 27(2), 283-301.
75.
Wilens, T.E., Biederman, J., Mick, E., Faraone, S.V., & Spencer, T. (1997). Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. Journal of Nervous and Mental Disease, 185(8), 475-482.
76.
Wilens, T.E., Biederman, J., Millstein, R.B., Wozniak, J., Hahesy, A.L., & Spencer, T.J. (1999). Risk for substance use disorders in youths with child- and adolescent-onset bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 38(6), 680-685.
77.
Wilens, T.E., Biederman, J., Prince, J., Spencer, T.J., Faraone, S.V., Warburton, R., et al. (1996). Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. American Journal of Psychiatry, 153(9), 1147-1153.
78.
Wilens, T.E., Faraone, S.V., Biederman, J., & Gunawardene, S. (2003). Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics, 111(1), 179-185.
79.
Wilens, T.E., Gignac, M., Swezey, A., Monuteaux, M.C., & Biederman, J. (2006). Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. Journal of the American Academy of Child and Adolescent Psychiatry, 45(4), 408-414.
80.
Wilens, T.E., Haight, B.R., Horrigan, J.P., Hudziak, J.J., Rosenthal, N.E., Connor, D.F., et al. (2005). Bupropion XL in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled study. Biological Psychiatry, 57(7), 793-801.
81.
Williams, R.J., Goodale, L.A., Shay-Fiddler, M.A., Gloster, S.P., & Chang, S.Y. (2004). Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents. American Journal on Addictions , 13(4), 381-389.
82.
Woolverton, W.L., Cervo, L., & Johanson, C.E. (1984). Effects of repeated methamphetamine administration on methamphetamine self-administration in rhesus monkeys. Pharmacology, Biochemistry, and Behavior, 21(5), 737-741.
